News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-21 4:1:52 am Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update GlobeNewsWire
2024-03-20 4:0:0 am Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis GlobeNewswire
2024-03-08 5:50:20 am Jim Cramer’s 10 Latest Stock Picks This Week Insider Monkey
2024-02-27 7:11:54 am Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 Insider Monkey
2024-02-27 5:0:0 am Cabaletta Bio to Participate in Upcoming Investor Conferences in March GlobeNewswire
2024-02-01 1:30:0 pm Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis GlobeNewswire
2024-01-31 5:0:0 am Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference GlobeNewswire
2024-01-09 3:27:34 am Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%? Simply Wall St.
2024-01-08 4:0:0 am Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information